Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash from Investing Activities (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 2 years of Cash from Investing Activities data on record, last reported at $33.5 million in Q4 2022.

  • For Q4 2022, Cash from Investing Activities changed N/A year-over-year to $33.5 million; the TTM value through Dec 2022 reached -$455.4 million, changed N/A, while the annual FY2025 figure was $188.8 million, 236.5% up from the prior year.
  • Cash from Investing Activities reached $33.5 million in Q4 2022 per AVIR's latest filing, up from -$487.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $33.5 million in Q4 2022 and bottomed at -$487.0 million in Q3 2022.